Diabetes Research and Clinical Practice
Volume 87, Issue 2 , Pages 233-239 , February 2010

Association between plasma high-sensitivity C-reactive protein and insulin resistance and white matter lesions in Japanese type 2 diabetic patients

  • Futoshi Anan

      Affiliations

    • Department of Cardiology, Oita Red Cross Hospital, Oita 870-0033, Japan
    • First Department of Internal Medicine, Oita University, Oita 870-5593, Japan
    • Corresponding Author InformationCorresponding author at: Department of Cardiology, Oita Red Cross Hospital, 3-2-37 Chiyomachi, Oita 870-0033, Japan. Tel.: +81 97 532 6181; fax: +81 97 533 1207.
    • ,
  • Takayuki Masaki

      Affiliations

    • First Department of Internal Medicine, Oita University, Oita 870-5593, Japan
    • ,
  • Hidetoshi Kikuchi

      Affiliations

    • First Department of Internal Medicine, Oita University, Oita 870-5593, Japan
    • ,
  • Tetsu Iwao

      Affiliations

    • Department of Cardiology, Oita Red Cross Hospital, Oita 870-0033, Japan
    • ,
  • Tsuyoshi Shimomura

      Affiliations

    • Department of Neurosurgery, Oita Red Cross Hospital, Oita 870-0033, Japan
    • ,
  • Yoshikazu Umeno

      Affiliations

    • Department of Endocrinology, Oita Red Cross Hospital, Oita 870-0033, Japan
    • ,
  • Nobuoki Eshima

      Affiliations

    • Department of Biostatistics, Oita University, Oita 870-5593, Japan
    • ,
  • Tetsunori Saikawa

      Affiliations

    • Department of Cardiovascular Science and School of Medicine, Oita University, Oita 870-5593, Japan
    • ,
  • Hironobu Yoshimatsu

      Affiliations

    • First Department of Internal Medicine, Oita University, Oita 870-5593, Japan

Received 18 May 2009 ,Revised 16 October 2009 ,Accepted 26 October 2009.

References 

  1. Pantoni L, Garcia JH. The significance of cerebral white matter abnormalities 100 years after Binswanger's report. Stroke. 1995;26:1293–1301
  2. Wong TY, Klein R, Sharrett AR, Couper DJ, Klein BE, Liao DP, et al. Cerebral white matter lesions, retinopathy, and incident clinical stroke. JAMA. 2002;288:67–74
  3. Vermeer SE, Hollander M, van Dijk EJ, Hofman A, Koudstaal PJ, Breteler MM. Silent brain infarcts and white matter lesions increase stroke risk in the general population: the Rotterdam Scan Study. Stroke. 2003;34:1126–1129
  4. Longstreth WT, Manolio TA, Arnold A, Burke GL, Bryan N, Jungreis CA, et al. Clinical correlates of white matter findings on cranial magnetic resonance imaging of 3301 elderly people. The Cardiovascular Health Study. Stroke. 1996;27:1274–1282
  5. Schmidt R, Launer LJ, Nilsson LG, Pajak A, Sans S, Berger K, et al. CASCADE Consortium. A magnetic resonance imaging of midlife blood pressure to late-life cognitive decline and brain morphology. Diabetes. 2004;53:687–692
  6. Ross R. Atherosclerosis—an inflammatory disease. N. Engl. J. Med. 1999;340:115–126
  7. Ridker PM. High-sensitivity C-reactive protein: potential adjunct for global risk assessment in the primary prevention of cardiovascular disease. Circulation. 2001;336:973–979
  8. Cesari M, Penninx BW, Newman AB, Kritchevsky SB, Nicklas BJ, Sutton-Tyrrell K, et al. Inflammatory markers and onset of cardiovascular events: results from the health ABC study. Circulation. 2003;108:2317–2322
  9. Hoshi T, Kitagawa K, Yamagami H, Furukado S, Hougaku H, Hori M. Relations of serum high-sensitivity C-reactive protein and interleukin-6 levels with silent brain infraction. Stroke. 2005;36:768–772
  10. Hassan A, Hunt BJ, O'Sullivan M, Parmar K, Bamford JM, Briley D, et al. Markers of endothelial dysfunction in lacunar infarction and ischaemic leukoaraiosis. Brain. 2003;126:424–432
  11. van Dijk EJ, Prins ND, Vermeer SE, Vrooman HA, Hofman A, Koudstaal PJ, et al. C-reactive protein and cerebral small-vessel disease: the Rotterdam Scan Study. Circulation. 2005;112:900–905
  12. Reaven GM. Role of insulin resistance in human disease. Diabetes. 1998;37:1595–1607
  13. DeFronzo RA, Ferrannini E. Insulin resistance. A multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia, and atherosclerotic cardiovascular disease. Diabetes Care. 1991;14:173–194
  14. Jeppesen J, Hansen TW, Rasmussen S, Ibsen H, Torp-Pedersen C, Madsbad S. Insulin resistance, the metabolic syndrome, and risk of incident cardiovascular disease: a population-based study. JACC. 2007;49:2112–2119
  15. Liao D, Sloan RP, Cascio WEWE, Folsom AR, Liese AD, Evans GW, et al. Multiple metabolic syndrome is associated with lower heart rate variability. The Atherosclerosis Risk in Communities Study. Diabetes Care. 1998;21:2116–2122
  16. Mancia G, De Backer G, Dominiczak A, Cifkova R, Fagard R, Germano G, et al. ESH-ESC practice guidelines for the management of arterial hypertension: ESH-ESC task force on the management of arterial hypertension. J. Hypertens. 2007;25:1751–1762
  17. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin. Chem. 1972;18:499–502
  18. Matthews DR, Hosker JP, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 1985;28:412–419
  19. Taniguchi A, Fukushima M, Sakai M, Miwa K, Makita T, Nagata I, et al. Remnant-like particle cholesterol, triglyceride, and insulin resistance in nonobese Japanese type 2 diabetic patients. Diabetes Care. 2000;23:1766–1769
  20. Rifai N, Tracy RP, Ridker PM. Clinical efficacy of an automated high-sensitivity C-reactive protein assay. Clin. Chem. 1999;45:2136–2141
  21. Pearson TA, Mensah GA, Alexander RW, Anderson JL, Cannon RO, Criqui M, et al. Markers of inflammation and cardiovascular disease: application to clinical and public health practice: a statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation. 2003;107:499–511
  22. Frohlich M, Imhof A, Berg G, Hutchinson WL, Pepys MB, Boeing H, et al. Association between C-reactive protein and features of the metabolic syndrome: a population-based study. Diabetes Care. 2000;23:1835–1839
  23. Breteler MM, van Swieten JC, Bots ML, Grobbee DE, Claus JJ, van den Hout JH, et al. Cerebral white matter lesions, vascular risk factors, and cognitive function in a population-based study: the Rotterdam Study. Neurology. 1994;44:1246–1252
  24. Shimada K, kawamoto A, Matsubayashi K, Ozawa T. Silent cerebrovascular disease in the elderly. Correlation with ambulatory pressure. Hypertension. 1990;16:692–699
  25. Sierra C, de la Sierra A, Mercader J, Gómez-Angelats E, Urbano-Márquez A, Coca A. Silent cerebral white matter lesions in middle-aged essential hypertensive patients. J. Hypertens. 2002;20:519–524
  26. Libby P, Ridker PM. Novel inflammatory markers of coronary risk: theory versus practice. Circulation. 1999;100:1148–1150
  27. del Zoppo G, Ginis I, Hallenbeck JM, Iadecola C, Wang X, Feuerstein GZ. Inflammation and stroke: putative role for cytokines, adhesion molecules and iNOS in brain response to ischemia. Brain Pathol. 2000;10:95–112
  28. Pasceri V, Willerson JT, Yeh. ET. Direct proinflammatory effect of C-reactive protein on human endothelial cells. Circulation. 2000;102:2165–2168
  29. Venugopal SK, Devaraj S, Yuhanna I, Shaul P, Jialal I. Demonstration that C-reactive protein decreases eNOS expression and bioactivity in human aortic endothelial cells. Circulation. 2002;106:1439–1441
  30. Nelken NA, Coughlin SR, Gordon D, Wilcox JN. Monocyte chemoattractant protein-1 in human atheromatous plaques. J. Clin. Invest. 1991;88:1121–1127
  31. Schmeisser A, Soehnlein O, Illmer T, Lorenz HM, Eskafi S, Roerick O. Biochem. Biophys. Res. Commun. 2004;325:532–540
  32. Napoli C, de Nigris F, Williams-Ignarro S, Pignalosa O, Sica V, Ignarro LJ. Nitic oxide and atherosclerosis: an update. Nitric Oxide. 2006;15:265–279
  33. Schmidt R, Launer LJ, Nilsson LG, Pajak A, Sans S, Berger K, et al. CASCADE Consortium. Magnetic resonance imaging of the brain in diabetes: the Cardiovascular Determinants of Dementia (CASCADE) Study. Diabetes. 2004;53:687–692
  34. Jongen C, van der Grond J, Kappelle LJ, Biessels GJ, Viergever MA, Pluim JP Utrecht Diabetic Encephalopathy Study Group. Automated measurement of brain and white matter lesion volume in type 2 diabetes mellitus. Diabetologia. 2007;50:1509–1516
  35. Stout RW. Insulin and atheroma: 20-yr perspective. Diabetes Care. 1990;13:631–654
  36. Kuboki K, Jiang ZY, Takahara N, Ha SW, Igarashi M, Yamauchi T, et al. Regulation of endothelial constitutive nitric oxide synthase gene expression in endothelial cells and in vivo: a specific vascular action of insulin. Circulation. 2000;101:676–681
  37. Steinberg HO, Paradisi G, Hook G, Crowder K, Cronin J, Baron AD. Free fatty acid elevation impairs insulin-mediated vasodilation and nitric oxide production. Diabetes. 2000;49:1231–1238
  38. Arcaro G, Cretti A, Balzano S, Lechi A, Muggeo M, Bonora E, et al. Insulin causes endothelial dysfunction in humans: sites and mechanisms. Circulation. 2002;105:576–582
  39. Wada M, Nagasawa H, Kurita K, Koyama S, Arakawa S, Kawanami T, et al. Microalbuminuria is a risk factor for cerebral small vessel disease in community-based elderly subjects. J. Neurol. Sci. 2007;255:27–34
  40. Lender D, Arauz-Pacheco C, Breen L, Mora-Mora P, Ramirez LC, Raskin P. A double blind comparison of the effects of amlodipine and enalapril on insulin sensitivity in hypertensive patients. Am. J. Hypertens. 1999;12:298–303
  41. Anan F, Takahashi N, Ooie T, Yufu K, Hara M, Nakagawa M, et al. Effects of valsartan and perindopril combination therapy on left ventricular hypertrophy and aortic stiffness in patients with essential hypertension. Eur. J. Clin. Pharmacol. 2005;61:353–359
  42. Albert MA, Danielson E, Rifai N, Ridker PM, Investigators PRINCE. Effect of statin therapy on C-reactive protein levels: the pravastatin inflammation/CRP evaluation (PRINCE): a randomized trial and cohort study. JAMA. 2001;286:64–70
  43. Satoh N, Ogawa Y, Usui T, Tagami T, Kono S, Uesugi H, et al. Antiatherogenic effect of pioglitazone in type 2 diabetic patients irrespective of the responsiveness to its antidiabetic effect. Diabetes Care. 2003;26:2493–2499

PII: S0168-8227(09)00465-3

doi: 10.1016/j.diabres.2009.10.017

Diabetes Research and Clinical Practice
Volume 87, Issue 2 , Pages 233-239 , February 2010

Article Tools

* Image Usage & Resolution